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Abstract
Along with the rapid evolution of transcatheter interventions, interventional cardiolo-
gists are playing more and more important role in the care of cardiovascular disease. 
The consequence of rapid change in the landscape has been fostering new and improved 
relationships between interventional cardiologists and cardiac surgeons and the formu-
lation of Heart Team to facilitate patient management. A hybrid strategy is a combina-
tion of tools available only in the catheterization laboratory with those available only in 
the operative room in order to gain maximum profit from both of them. In the current 
era, the continuous development in transcatheter procedures along with the adoption of 
minimally invasive surgical approaches makes hybrid strategy an attractive alternative 
to conventional surgical or transcatheter techniques for any given set of cardiovascu-
lar diseases. In the areas of coronary revascularization, valve repair or replacement, and 
ablation for atrial fibrillation, hybrid approaches have shown great benefit especially in 
high-risk cases. With the technological evolutions in the treatment of cardiovascular dis-
ease, the Heart Team approach utilizing the expertise of all relevant specialties will be 
more and more invaluable in facilitating optimal patient selection, procedural planning, 
complication management, postprocedural care, and patient outcomes.
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1. Introduction
A hybrid approach combines the treatments traditionally available only in the catheteriza-
tion laboratory with those traditionally available only in the operative room in order to obtain 
maximum benefit from both procedures. The continuous evolution of transcatheter technology 
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along with the adoption of minimally invasive surgical approaches make hybrid procedures 
an attractive alternative to conventional surgical or interventional techniques for a wide variety 
of cardiovascular diseases [1–3]. Angelini et al. reported the first case series of hybrid coronary 
artery revascularization in 1996 [4]. Since then, along with technological advancement, hybrid 
procedures are currently applied not only for coronary artery disease, but also for valvular 
heart disease, arrhythmia, congenital heart disease, aortic diseases, and peripheral vascular 
disease.
As a result of rapid evolution of transcatheter techniques, interventional cardiologists are 
playing a central role in the management of cardiovascular diseases. For a success of hybrid 
approach, a formulation of Heart Team combined with good collaboration between interven-
tional cardiologists and cardiac surgeons is encouraged to facilitate patient management. The 
indications and patient selection for hybrid procedures need to be well discussed in Heart Team.
2. Hybrid coronary revascularization (HCR)
2.1. Rationale of HCR
Despite the increasing use of percutaneous coronary intervention (PCI) for coronary artery 
disease during the past decade [5], coronary artery bypass grafting (CABG) remains the gold 
standard for multivessel coronary artery disease or left main disease [6]. A number of major 
trials such as SYNTAX [7], ASCERT [8], and FREEDOM [9] reported superior long-term sur-
vival rates of CABG compared with PCI.
The main factor of the superiority of CABG over PCI is the use of left internal mammary artery 
(LIMA) to left anterior descending (LAD) artery [10, 11]. The excellent long-term patency of 
LIMA to LAD graft has been established [12–14], whereas the long-term outcomes of other 
conduits such as saphenous vein graft and radial artery have been reported to be poorer than 
those of LIMA. The patency rates of saphenous vein grafts were 71–87% at 1-year after sur-
gery in previous studies [15–17], and up to 50% at 10-years [15–19].
On the other hand, newer generation of drug-eluted stents are associated with fewer reste-
nosis and repeat revascularization compared to conventional bare metal stents [20], and are 
associated with similar or even better long-term patency rates than saphenous vein grafts 
[11, 17, 21–23]. Thus, the combination of LIMA-LAD bypass and PCI using new generation 
of drug-eluting stents to non-LAD lesions takes the advantage of both procedures. The ratio-
nale of HCR is to combine the survival benefit and high patency rates of LIMA graft with the 
lower restenosis rates of new generation drug-eluting stents for non-LAD lesions [11, 24, 25].
2.2. Indications of HCR
HCR is applicable in patients having multivessel coronary artery disease with CABG-suitable 
LAD disease and PCI-suitable non-LAD disease [1, 11, 26–28]. HCR takes the most advan-
tage in patients with comorbidities such as diabetes mellitus, obesity, chronic kidney disease, 
chronic occlusive pulmonary disease, and advanced age [11, 28], because these comorbidities 
are known to increase the risk of conventional CABG.
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On the other hand, there is a couple of situations where HCR is not suitable, such as left sub-
clavian artery stenosis, nonusable LIMA graft due to prior radiation to the left chest, intramyo-
cardial LAD, previous stent to the target lesions, and extensive calcification on LAD [27, 29].
American guidelines for HCR demonstrate that HCR is reasonable in patients with one or 
more of the following: limitations to traditional CABG, such as heavily calcified proximal 
aorta or poor target vessels for CABG but amenable to PCI; lack of suitable graft conduits; 
unfavorable LAD for PCI such as excessive vessel tortuosity or chronic total occlusion with 
Class IIa recommendation with level of evidence of B. Also, HCR may be reasonable as an 
alternative to multivessel PCI or CABG in an attempt to improve the overall risk-benefit ratio 
of the procedures with Class IIb recommendation with level of evidence of C [3].
2.3. Techniques of HCR
Several techniques have been reported for achieving minimally invasive CABG [1]. 
Thoracoscopic endoscopic CABG; LIMA graft is harvested with the use of thoracoscopy 
through a port-access approach. The LIMA-to-LAD anastomosis is then performed by hand 
on the beating heart using specially designed stabilizers and retractors [2]. Robotically 
assisted CABG; LIMA graft is harvested with an assistance of robot followed by a hand-sewn 
LIMA-to-LAD anastomosis on the beating heart [3]. Totally endoscopic CABG, LIMA harvest 
and the anastomosis are performed endoscopically with the robot. The anastomosis can be 
performed on the beating heart or on cardiopulmonary bypass on an arrested heart.
HCR can be performed either as a one-staged or a two-staged procedure. A two-staged pro-
cedure is defined as a PCI and CABG performed separately by hours or days. A one-staged 
HCR is defined as PCI and CABG performed in a hybrid-operating room in one operative 
setting. The advantages of one-staged HCR include complete revascularization with minimal 
patient discomfort, intraoperative confirmation of LIMA-to-LAD anastomosis, and easy con-
version to conventional CABG if needed [29]. However, bleeding concerns due to dual anti-
platelet therapy and incomplete heparin reversal, as well as acute stent thrombosis possibility 
are disadvantages of one-staged HCR [11].
In a two-staged approach, there is a concern of adverse coronary events between the proce-
dures because patients are incompletely revascularized. When PCI is preceded, CABG needs 
to be performed under the effect of dual antiplatelet therapy, which leads to significant bleed-
ing risk. On the other hand, when CABG is preceded, PCI can be performed under the protec-
tion of the LIMA-to-LAD graft and the ability to verify the patency of the LIMA-to-LAD graft 
while avoiding the risk of bleeding due to dual antiplatelet therapy. Therefore, CABG-first 
strategy for two-staged HCR is preferable.
2.4. Outcomes of HCR
The surgical outcomes of previous studies regarding HCR are summarized in Table 1. The 
30-day mortality after HCR ranged from 0 to 2.4%. LIMA patency is reported to be over 90%. 
The event-free survival rate ranged from 83 to 100%, whereas the incidence of major adverse 
cardiac and cerebrovascular events (MACCEs) ranged from 0 to 12.2%. However, the sample 
size of each study was relatively small.
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Zhu et al. performed a meta-analysis to compare the short-term outcomes of HCR with those of 
CABG for multivessel coronary artery disease. They found that HCR was noninferior to CABG 
in terms of the incidence of death, myocardial infarction, stroke, and renal failure, whereas HCR 
was associated with less blood transfusion and shorter length of stay in hospital [30]. Halkos 
et al. compared the outcomes of 147 HCR cases with matched off-pump CABG cases. They 
reported 5-year survival rate and the incidence of MACCE were similar between HCR and off-
pump CABG, whereas the need for repeated revascularization was higher in HCR group [31].
3. Transcatheter treatment for aortic valve disease
For the treatment of severe symptomatic aortic stenosis, surgical aortic valve replacement has 
been the gold standard. The advent and rapidly widespread adoption of transcatheter aortic 
valve replacement (TAVR) has now resulted in it becoming the option for patients who would 
have been considered inoperable or prohibitively high surgical risk [32]. Excellent mid-term 
Study Year Number of pts Follow-up 
(months)
30-day mortality 
(%)
MACCE (%) Event-free 
survival (%)
Angelini et 
al. [4]
1996 6 – 0 – 89
Leacche et al. 
[25]
2013 80 1 – 2.5 91
Rab et al. [53] 2012 22 38.8 ± 22 0 0 95
Lewis et al. 
[54]
1999 14 1.44 0 – 93
Isomura et al. 
[55]
2000 37 24 1.4 – 92
Presbitero et 
al. [56]
2001 42 18 2.4 12.2 83
Lee et al. [57] 2004 6 12 0 0 –
Repossini et 
al. [58]
2013 166 64.6 ± 12.0 1.2 12 83 (at 5 years)
Gilard et al. 
[59]
2007 70 33 1.4 – 97
Kon et al. [60] 2008 15 12 0 – 93
Vassiliades et 
al. [61]
2006 47 7 0 – 90
Bonatti et al. 
[62]
2008 5 6 0 – 100
Note: MACCE; major adverse cardiac and cerebrovascular events.
Table 1. Outcomes of hybrid coronary revascularization.
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and long-term outcomes after TAVR have been reported [33, 34], and indications of TAVR are 
expanding to severe aortic valve regurgitation associated with moderate aortic valve stenosis 
and valve-in-valve procedures for surgical bioprosthetic valve failure.
TAVR procedures are now shifting to percutaneous approach and even general anesthesia is 
not mandatory. The percutaneous transfemoral route is the preferred approach in the majority 
of the cases due to its associated advantages [35]. Although some centers reported that trans-
apical and transfemoral approach resulted in the similar outcomes [36], transapical approach 
is usually associated with poorer outcomes than transfemoral approach [37]. Interventional 
cardiologists possess the required skills for transfemoral TAVR including the handling of 
guidewires, catheters, and image selection. They can even take care of technical complica-
tions associated with TAVR, such as coronary obstruction and conduction disturbance by 
performing PCI or implanting pacemaker. Although interventional cardiologists can take a 
lead in TAVR procedures, surgeons still play an important role in managing life-threatening 
complications such as aortic root rupture, cardiac tamponade, and vascular complications. 
Those complications cannot be managed percutaneously and surgical interventions are the 
only viable rescue option. Furthermore, surgeons have the skill to ensure procedural success 
in patients whom transfemoral approach is not applicable. For the success of transapical and 
transaortic TAVR procedures, surgeons play a crucial role and they should be familiar with 
individual cases and technical aspects.
Postprocedural care and rehabilitation are undoubtedly important in optimizing functional 
status and clinical outcomes [38]. Cardiologists can take the leading role in this area by virtue 
of familiarity with all aspects of general cardiology issues such as heart failure and arrhythmia 
in the management of these complex patients.
In conclusion, a good collaboration between interventional cardiologists and cardiac surgeons 
and formulation of a Heart Team is essential for the success of TAVR. The decision making for 
patients selection and surgical approach, the actual performance of procedure in the operat-
ing room, and postoperative care should be performed by a Heart Team approach [39].
4. Transcatheter treatment for mitral valve disease
4.1. Transcatheter mitral valve repair
The prevalence of mitral regurgitation is higher than other valvular heart diseases [40, 41]. 
Surgical mitral repair remains the gold standard for patients with primary mitral regurgita-
tion. However, there are a growing number of patients with mitral regurgitation underserved 
by surgical therapy due to prohibitive surgical risks. The recent development of transcatheter 
mitral valve technique provides an additional therapeutic option for some high-risk and inop-
erable patients [42, 43]. The optimal way to adjudicate innovative surgical and interventional 
mitral therapies is through a robust collaboration within a well-functioning Heart Team which 
includes not only cardiac surgeons and interventional cardiologists but also imaging specialists.
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The current leader in the field of transcatheter mitral repair device is the MitraClip (Abbott 
Vascular, Santa Clara, CA). This device is delivered in an antegrade transseptal approach 
across the atrial septum from the femoral vein to achieve an edge-to-edge direct leaflet approx-
imation (Figure 1). More than 30,000 patients worldwide have been treated with this proce-
dure to date. In the United States, a Society of Thoracic Surgeons (STS)/American College of 
Cardiology database analysis of the first 564 cases performed through August 2014 showed 
the average patient age was 83 years, with a median STS predicted risk of mortality for mitral 
valve repair and replacement of 7.9 and 10.0%, respectively. The majority of the patients had 
prohibitive surgical risks such as severe frailty, prior cardiac surgery, and end-stage heart 
failure. The procedural success rate was 91.8% with a 30-day operative mortality of 5.8% [43].
The randomized EVEREST II trial showed that the need for surgery for residual mitral regur-
gitation was significantly higher in patients who received MitraClip compared with those 
who underwent surgery at 1 year and 5 years; however, the MitraClip procedure was associ-
ated with superior safety and similar improvements in clinical outcomes [44, 45]. Currently, 
guidelines state that MitraClip can be considered in patients with severe primary mitral 
regurgitation who meet the echocardiographic criteria of eligibility, and are judged inoper-
able or at prohibitive surgical risk by a Heart Team [32, 46]. Further studies are needed to 
apply this technique to intermediate- or low-risk patients.
In conclusion, the MitraClip procedure has proven reasonable safety and efficacy in high-risk 
patients and is already considered as an established part of the mitral valve program in high-
volume centers. A multidisciplinary Heart Team approach will play a crucial role for careful 
patient selection and clinical application of the transcatheter interventions as a part of a suc-
cessful and multimodal mitral valve program [47].
Figure 1. MitraClip (Abbott Vascular, Santa Clara, CA) is a percutaneous mitral valve repair using anterior-posterior 
edge-to-edge direct leaflet approximation.
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4.2. Transcatheter mitral valve replacement
Unlike transcatheter mitral valve repair, the challenges of deploying and anchoring a func-
tional prosthetic device into the mitral valve annulus amid the intact subvalvular apparatus is 
more complex. As of January 2016, the total human experience with transcatheter mitral valve 
replacement implantation surpassed 50 cases, with half of those performed in the United 
States [43]. The preliminary outcomes have been promising so far.
The Tendyne device (Abbott Vascular, Santa Clara, CA) is a potentially fully retrievable 
trileaflet porcine pericardial valve with an impermeable nitinol skirt which has a prominent 
cuff positioned to rest on the intertrigonal aortomitral curtain [48] (Figure 2). The Tendyne is 
an intraannular valve that does not specifically capture the leaflets, and thus the primary clini-
cal target is patients with functional mitral regurgitation. The first US use of Tendyne device 
was in April 2015. Currently, multiple experienced centers have been chosen for the Food and 
Drug Administration (FDA) clinical trial for high risk patients inoperable for conventional 
mitral valve replacement. Several other devices for transcatheter mitral valve replacement are 
also in the stage of clinical investigation.
Despite continuing innovation, current transcatheter mitral valve replacement delivery systems 
remain large and the majority require a transapical retrograde approach to the mitral valve. 
Therefore, the collaboration between interventional cardiologists and surgeons is needed as 
with the transapical TAVR procedure.
5. Hybrid approach for atrial fibrillation
Nowadays the majority of ablations for symptomatic atrial fibrillation are catheter-cased. In 
the United States from 2000 to 2010, over 93,000 catheter ablations were performed for atrial 
Figure 2. Tendyne (Abbott Vascular, Santa Clara, CA) is a transapically delivered porcine pericardial valve for transcatheter 
mitral valve replacement.
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fibrillation [49]. However, the outcomes of catheter ablation for patients with significant valve 
disease and long-standing persistent atrial fibrillation remain poor [50]. For patients who 
have valvular heart disease or patients who are refractory to antiarrhythmic drugs or catheter 
ablation, surgical ablation called Cox-Maze procedure is recommended [51].
The hybrid approach for atrial fibrillation represents a collaborative between cardiac surgeons 
and cardiologists utilizing the strengths of both techniques in order to achieve outcomes that 
maximize the success rates and minimize the procedural complications. There are several 
potential advantages to a hybrid approach [50]. From a surgical standpoint, direct visualization 
allows surgeons to perform aggressive ablation at sites which may be challenging for catheter 
ablation due to risk of injuring esophagus or phrenic nerves, and also allows surgeons to confirm 
of transmurality of ablation. Moreover, the ability to exclude the left atrial appendage serves to 
potentially eliminate need for anticoagulation. On the other hand, catheter ablation allows more 
complex mapping of the left atrium for either complex fractionated atrial electrograms or rotors.
Hybrid procedures incorporate both an epicardial surgical ablation and endocardial catheter 
ablation [52]. The procedure can be done in either one-staged or two-staged fashion. The out-
comes of hybrid approach for atrial fibrillation in previous studies are shown in Table 2. While 
all procedures were done through minimally invasive approach, the approach varied with right, 
Study Year Number of pts Follow-up 
(months)
Mortality (%) Success rate off 
AA drugs (%)
Success rate on 
AA drugs (%)
Mahapatra et 
al. [63]
2011 15 20.7 ± 4.5 0 86.7 93.3
Krul et al. [64] 2011 31 12 0 86 –
Pison et al. 
[65]
2012 26 12 0 92 –
Muneretto et 
al. [66]
2012 36 30 0 77.7 91.6
Gersak et al. 
[67]
2012 50 24 4 87 –
La Meir et al. 
[68]
2013 35 12 0 91.4 –
Gehi et al. [69] 2013 101 12 2 60.7 73.3
Bisleri et al. 
[70]
2013 45 28 ± 1.7 0 88.9 –
Gersak et al. 
[71]
2014 73 12 0 52 80
Bulava et al. 
[72]
2015 50 12 0 84 94
Note: AA, antiarrhythmic.
Table 2. Outcomes of hybrid approach for atrial fibrillation.
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and bilateral thoracoscopic approaches as well as subxiphoid and laparoscopic access. Overall, 
hybrid ablation procedures are associated with low mortality which is up to 4%. High success 
rates are reported noting sinus rhythm off antiarrhythmic drugs in about 87% of cases and in 
about 92% when antiarrhythmic drugs are added.
In conclusion, for the success of the hybrid ablation for atrial fibrillation, a creation of a collaborative 
team between cardiac surgeons and electrophysiologists is crucial. This collaboration will permit 
important advances in improving the outcomes of procedure especially in challenging patients.
6. Conclusions
Nowadays, the cases of patients who suffer from cardiovascular disease are more and more 
complex. Along with the technological advancement, patients who used to be thought inop-
erable can be treated by a new technology with a reasonable risk. Interventional cardiologists 
tend to be more invasive in their field, whereas cardiac surgeons tend to seek for minimally 
invasive approach. There are advantages and disadvantages in both surgery and interventions. 
The rational for hybrid procedures is to achieve the best outcome by combining the strengths of 
both surgery and interventional procedures. The key point for the success of hybrid procedures 
is the collaboration between interventional cardiologists and cardiac surgeons. In the current era, 
patient selection and indications for each procedure must be well discussed in a well-functioning 
Heart Team.
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